United States to Guernsey Trade Analysis
for Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes
Detailed tariff information for Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes imports
Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes Tariff Rate
Limited data available; estimated at less than $100,000 USD
Year
2022
Trend
Stable with low volume
Special Rates
Preferential Rate
0%
Applicable under the UK-Guernsey Customs Union agreement, subject to proof of origin from the United States under specific trade agreements.
Additional Information
No additional information available.
Last updated: 1 year ago
News and Updates
Recent News
Limited Trade Activity for Antisera Products Between US and Guernsey
Recent trade data indicates minimal to no recorded trade of antisera, other blood fractions, and immunological products (HS Code: 3002) between the United States and Guernsey, reflecting the small scale of Guernsey's market and lack of specialized production.
October 2023
Impact: Negligible impact on trade due to the absence of significant bilateral trade in this category.
US Export Regulations Tighten on Biotechnological Products
The US Department of Commerce updated export controls on biotechnological products, including immunological products under HS Code 3002, which may indirectly affect small markets like Guernsey.
September 2023
Impact: Potential delays or increased compliance costs for any future trade with Guernsey, though current trade volume remains low.
Guernsey's Healthcare Import Trends Show No Focus on US Antisera
Guernsey's import data for healthcare products shows a preference for EU suppliers over US sources for immunological products, due to proximity and regulatory alignment.
August 2023
Impact: Reduced likelihood of significant US-Guernsey trade growth in this sector in the near term.
Policy Updates
US Export Control Update for Biotechnological Goods
The US Bureau of Industry and Security (BIS) has introduced stricter export licensing requirements for biotechnological products under HS Code 3002, citing national security and dual-use concerns. This may require additional documentation for exports to non-major trading partners like Guernsey.
